{
    "Trade/Device Name(s)": [
        "Access hsTnI"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K172783",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121214"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "May 3, 2018",
    "Summary Letter Received Date": "May 4, 2018",
    "Submission Date": "June 7, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cardiac troponin I (cTnI)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "UniCel DxI Access Immunoassay System",
        "Access UniCel DxI 800 Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access hsTnI assay for quantitative measurement of cardiac troponin I in human serum and plasma.",
    "Indications for Use Summary": "Quantitative determination of cardiac troponin I levels in human serum and plasma to aid in the diagnosis of myocardial infarction (MI) using the UniCel DxI Access Immunoassay System.",
    "fda_folder": "Clinical Chemistry"
}